In silico screening predicted that PGI2, beraprost, and GW0742 has the potential to bind to thyroid hormone β receptor (TRβ) and TRα.
Docking analysis predicts that that PGI2, beraprost, and GW0742 binds to residues thought to have allosteric control on the TR ligand binding site.
Luciferase reporter assays confirmed that beraprost and GW0742 display TRβ and TRα antagonistic properties.
Beraprost and GW0742 inhibit triiodothyronine (T3) induced vasodilation of rat mesenteric arteries.
Out data suggests that PGI2, has the ability to affect the long term function of cells through binding to and inactivating TRβ.